IGC Pharma Adds Mount Sinai as Clinical Site for CALMA Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 02 2026
0mins
IGC Pharma announced the addition of the Icahn School of Medicine at Mount Sinai in New York as a clinical site in the Company's Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer's disease. The addition of Mount Sinai comes as CALMA advances toward completion, with approximately 80% of targeted participants having completed trial participation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IGC
Wall Street analysts forecast IGC stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.276
Low
4.75
Averages
4.75
High
4.75
Current: 0.276
Low
4.75
Averages
4.75
High
4.75
No data
About IGC
IGC Pharma, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to develop treatments for Alzheimer's and metabolic disorders. The Company's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The Company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. It is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IGC Pharma Q1 Financial Results Analysis
- Earnings Performance: IGC Pharma reported a Q1 GAAP EPS of -$0.02, aligning with expectations, indicating stability in the company's profitability metrics.
- Revenue Insights: The company generated $0.32 million in revenue, reflecting a 3.0% year-over-year decline, yet surpassing market expectations by $0.09 million, suggesting a resilient demand despite challenges.
- Debt Management: As of March 31, 2026, IGC Pharma had total outstanding debt of approximately $917,000, with an additional $585,000 raised subsequently, highlighting proactive financing efforts.
- Financing Strategy: The company continues to explore financing alternatives, including potential equity and debt transactions, to support its clinical development programs and operations, underscoring its commitment to future growth.
See More
AKAN Stock Soars 300%, Set for Best Week Ever
- Stock Surge: AKAN's stock has surged 300% this week, marking its best weekly performance ever, reflecting improved investor sentiment across cannabis stocks, particularly after the U.S. Justice Department moved state-regulated marijuana to Schedule III, significantly boosting optimism in the sector.
- Micro Float Advantage: With a public float of only 534,420 shares following multiple reverse stock splits, AKAN's stock skyrocketed 1,700% in April, outperforming peers like Trulieve and Canopy Growth, highlighting the sensitivity of micro-float stocks to buying pressure during market rebounds.
- Strategic Shift: AKAN is increasingly focusing on the Canadian and European markets while building a telecommunications infrastructure through its First Towers & Fiber unit in Mexico, which is expected to generate $2 million in contracted cash flow over the next decade, providing a hedge against the volatility typical in pure cannabis companies.
- Market Sentiment High: Retail sentiment for AKAN on Stocktwits is extremely bullish, with message volumes surging 231,800% over the past month, indicating strong investor interest in the stock, despite potential short-term corrections, as traders remain optimistic about its future performance.
See More
Highlights from New to The Street Broadcast
- Rich Program Content: Tonight's episode #746 of New to The Street will air on Bloomberg Television, reaching millions of households across the U.S., MENA, and Latin America, showcasing innovations and developments from various companies.
- Industry Leaders Speak: Dr. Jonathan C. Javitt, CEO of NRx Pharmaceuticals, discusses the company's innovative pipeline in critical care and neuropsychiatric treatments, emphasizing its leading position in the healthcare sector.
- Digital Transformation: Performance Golf, a leading digital golf instruction platform, is transforming how players improve their game worldwide, demonstrating the potential of technology in traditional sports.
- Diverse Sponsorships: The program is further supported by commercial sponsorships from Medicus Pharma, IGC Pharma, Roadzen, and Lantern Pharma, enhancing its influence in the healthcare, AI, and technology sectors.
See More
DOJ Updates Marijuana Classification Policy
- Policy Change Context: The U.S. Department of Justice has formally proposed reclassifying state-licensed medical marijuana from Schedule I to Schedule III, which, while not legalizing marijuana, reduces regulatory hurdles and offers tax relief for licensed operators, expected to enhance medical research and expand access to treatments.
- Market Reaction: Following the announcement, shares of Tilray (TLRY), Canopy Growth (CGC), Aurora Cannabis (ACB), and IGC Pharma (IGC) fell between 2-5% in morning trading despite previous gains, indicating a cautious market response to the policy change.
- Investor Sentiment: Retail sentiment on Stocktwits for TLRY, CGC, ACB, and IGC turned ‘extremely bullish’ with message volumes surging, reflecting optimistic expectations for the cannabis industry's revival, with some users claiming Tilray will become the “king of the U.S. cannabis market.”
- Akanda Corp. Outperformance: In contrast to major cannabis stocks, Akanda Corp. (AKAN) saw a 6% increase, extending a remarkable 215% surge from the previous session, with investors debating whether this explosive rally is driven by optimism over cannabis reclassification or the stock's low float.
See More
Trump Signs Executive Order to Reclassify Marijuana
- Reclassification Process: Trump signed an executive order to reclassify marijuana from Schedule I to Schedule III, similar to Tylenol with codeine, aimed at recognizing legitimate medical uses and expediting research, expected to take effect on Wednesday.
- Positive Market Reaction: Following the announcement, Tilray (TLRY) shares rose 13%, while Aurora Cannabis (ACB), Canopy Growth (CGC), and IGC Pharma Inc (IGC) increased by 10%, 20%, and 6% respectively, with AdvisorShares Pure US Cannabis ETF (MSOS) climbing 23%, indicating strong market optimism.
- Recognition of Medical Use: Trump emphasized that the reclassification does not legalize recreational marijuana but aims to accelerate medical research, reflecting government acknowledgment of marijuana's potential medical value, which could drive R&D and market expansion for related companies.
- Investor Sentiment Surge: On Stocktwits, retail sentiment for TLRY and CGC is trending in the 'extremely bullish' territory with high message volume, indicating strong investor confidence in the future of the cannabis industry, with TLRY gaining 70% and CGC 16% over the past 12 months.
See More
IGC Pharma Reports Significant Reduction in Net Loss
- Net Loss Reduction: For the nine months ending December 31, 2025, IGC Pharma reported a net loss of $4.1 million, indicating improvements in cost control and operational efficiency, although financial challenges remain.
- Revenue Performance: The company's revenue during the same period stood at $869,000, reflecting insufficient market demand and challenges in product sales, necessitating enhanced marketing efforts to boost revenue levels.
- Financial Health Assessment: Despite the reduction in net loss, IGC Pharma must focus on cash flow and financing strategies to ensure future operations and R&D investments, maintaining competitiveness in the market.
- Investor Attention: The financial performance of IGC Pharma has drawn investor interest, and Seeking Alpha's Quant Rating may influence market perceptions of its stock, prompting investors to closely monitor subsequent financial reports and market developments.
See More
IGC Pharma Q1 Financial Results Analysis
- Earnings Performance: IGC Pharma reported a Q1 GAAP EPS of -$0.02, aligning with expectations, indicating stability in the company's profitability metrics.
- Revenue Insights: The company generated $0.32 million in revenue, reflecting a 3.0% year-over-year decline, yet surpassing market expectations by $0.09 million, suggesting a resilient demand despite challenges.
- Debt Management: As of March 31, 2026, IGC Pharma had total outstanding debt of approximately $917,000, with an additional $585,000 raised subsequently, highlighting proactive financing efforts.
- Financing Strategy: The company continues to explore financing alternatives, including potential equity and debt transactions, to support its clinical development programs and operations, underscoring its commitment to future growth.
See More
AKAN Stock Soars 300%, Set for Best Week Ever
- Stock Surge: AKAN's stock has surged 300% this week, marking its best weekly performance ever, reflecting improved investor sentiment across cannabis stocks, particularly after the U.S. Justice Department moved state-regulated marijuana to Schedule III, significantly boosting optimism in the sector.
- Micro Float Advantage: With a public float of only 534,420 shares following multiple reverse stock splits, AKAN's stock skyrocketed 1,700% in April, outperforming peers like Trulieve and Canopy Growth, highlighting the sensitivity of micro-float stocks to buying pressure during market rebounds.
- Strategic Shift: AKAN is increasingly focusing on the Canadian and European markets while building a telecommunications infrastructure through its First Towers & Fiber unit in Mexico, which is expected to generate $2 million in contracted cash flow over the next decade, providing a hedge against the volatility typical in pure cannabis companies.
- Market Sentiment High: Retail sentiment for AKAN on Stocktwits is extremely bullish, with message volumes surging 231,800% over the past month, indicating strong investor interest in the stock, despite potential short-term corrections, as traders remain optimistic about its future performance.
See More
Highlights from New to The Street Broadcast
- Rich Program Content: Tonight's episode #746 of New to The Street will air on Bloomberg Television, reaching millions of households across the U.S., MENA, and Latin America, showcasing innovations and developments from various companies.
- Industry Leaders Speak: Dr. Jonathan C. Javitt, CEO of NRx Pharmaceuticals, discusses the company's innovative pipeline in critical care and neuropsychiatric treatments, emphasizing its leading position in the healthcare sector.
- Digital Transformation: Performance Golf, a leading digital golf instruction platform, is transforming how players improve their game worldwide, demonstrating the potential of technology in traditional sports.
- Diverse Sponsorships: The program is further supported by commercial sponsorships from Medicus Pharma, IGC Pharma, Roadzen, and Lantern Pharma, enhancing its influence in the healthcare, AI, and technology sectors.
See More
DOJ Updates Marijuana Classification Policy
- Policy Change Context: The U.S. Department of Justice has formally proposed reclassifying state-licensed medical marijuana from Schedule I to Schedule III, which, while not legalizing marijuana, reduces regulatory hurdles and offers tax relief for licensed operators, expected to enhance medical research and expand access to treatments.
- Market Reaction: Following the announcement, shares of Tilray (TLRY), Canopy Growth (CGC), Aurora Cannabis (ACB), and IGC Pharma (IGC) fell between 2-5% in morning trading despite previous gains, indicating a cautious market response to the policy change.
- Investor Sentiment: Retail sentiment on Stocktwits for TLRY, CGC, ACB, and IGC turned ‘extremely bullish’ with message volumes surging, reflecting optimistic expectations for the cannabis industry's revival, with some users claiming Tilray will become the “king of the U.S. cannabis market.”
- Akanda Corp. Outperformance: In contrast to major cannabis stocks, Akanda Corp. (AKAN) saw a 6% increase, extending a remarkable 215% surge from the previous session, with investors debating whether this explosive rally is driven by optimism over cannabis reclassification or the stock's low float.
See More
Trump Signs Executive Order to Reclassify Marijuana
- Reclassification Process: Trump signed an executive order to reclassify marijuana from Schedule I to Schedule III, similar to Tylenol with codeine, aimed at recognizing legitimate medical uses and expediting research, expected to take effect on Wednesday.
- Positive Market Reaction: Following the announcement, Tilray (TLRY) shares rose 13%, while Aurora Cannabis (ACB), Canopy Growth (CGC), and IGC Pharma Inc (IGC) increased by 10%, 20%, and 6% respectively, with AdvisorShares Pure US Cannabis ETF (MSOS) climbing 23%, indicating strong market optimism.
- Recognition of Medical Use: Trump emphasized that the reclassification does not legalize recreational marijuana but aims to accelerate medical research, reflecting government acknowledgment of marijuana's potential medical value, which could drive R&D and market expansion for related companies.
- Investor Sentiment Surge: On Stocktwits, retail sentiment for TLRY and CGC is trending in the 'extremely bullish' territory with high message volume, indicating strong investor confidence in the future of the cannabis industry, with TLRY gaining 70% and CGC 16% over the past 12 months.
See More
IGC Pharma Reports Significant Reduction in Net Loss
- Net Loss Reduction: For the nine months ending December 31, 2025, IGC Pharma reported a net loss of $4.1 million, indicating improvements in cost control and operational efficiency, although financial challenges remain.
- Revenue Performance: The company's revenue during the same period stood at $869,000, reflecting insufficient market demand and challenges in product sales, necessitating enhanced marketing efforts to boost revenue levels.
- Financial Health Assessment: Despite the reduction in net loss, IGC Pharma must focus on cash flow and financing strategies to ensure future operations and R&D investments, maintaining competitiveness in the market.
- Investor Attention: The financial performance of IGC Pharma has drawn investor interest, and Seeking Alpha's Quant Rating may influence market perceptions of its stock, prompting investors to closely monitor subsequent financial reports and market developments.
See More
